The GEO Group (NYSE:GEO), a leading provider of government-contracted services, announced on Monday that its wholly-owned subsidiary, BI Incorporated, has been awarded a significant new contract by U.S. Immigration and Customs Enforcement (ICE).
Parsons Corporation (NYSE:PSN) has secured a $30 million contract expansion and a strategic novation to the U.S. Space Development Agency (SDA), marking a major transition for the Department of Defense’s "Blackjack" satellite program.
Greenwich LifeSciences (NASDAQ:GLSI) provided a comprehensive year-end update on Monday for its pivotal Phase III clinical trial, FLAMINGO-01.
The trial is evaluating GLSI-100, a Fast Track-designated immunotherapy designed to prevent breast cancer recurrence in HER2-positive patients.
Honeywell International (NASDAQ:HON) issued a comprehensive update to its financial projections on Monday, recalibrating its 2025 guidance to account for the strategic spin-off of its Advanced Materials business.
KalVista Pharmaceuticals (NASDAQ:KALV) has received marketing and manufacturing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for EKTERLY (sebetralstat), establishing it as the first and only oral on-demand treatment for hereditary angioedema (HAE) in the country.
Ennis (NYSE:EBF), a major manufacturer of printed business products, reported an increase in third-quarter profitability on Monday, as significant margin expansion helped the company overcome a softer nine-month revenue trend.
Uber Technologies (NYSE:UBER) and Lyft (NASDAQ:LYFT) are joining forces with Chinese tech giant Baidu (NASDAQ:BIDU) to launch driverless taxi trials in the United Kingdom next year, a strategic pivot that intensifies the global race to commercialize autonomous mobility.
STMicroelectronics NV (NYSE:STM) has entered a strategic agreement with Italian robotics firm Oversonic to integrate cognitive humanoid robots into its global manufacturing and logistics network.
Alvotech (NASDAQ:ALVO) achieved a significant milestone in the competitive biologics market on Monday, announcing the European debut of Gobivaz, the first biosimilar to the blockbuster inflammatory drug Simponi to reach the market anywhere in the world.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal step in moving the blockbuster treatment into earlier, potentially curative stages of breast cancer.
Incyte Biosciences Japan G.K. has secured regulatory clearance from Japan’s Ministry of Health, Labour and Welfare for Minjuvi, marking the first time a dual-targeted CD19 and CD20 immunotherapy combination has been authorized for patients with follicular lymphoma in the country.
Samsung Biologics, the world’s leading contract development and manufacturing organization, has reached an agreement to acquire Human Genome Sciences from GSK (NYSE:GSK), marking the South Korean firm’s first physical manufacturing footprint in the United States.
